To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

To demonstrate the relative bioequivalency study of dosage forms of Clemastine 2.68 mg tablets.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergy Hypersensitivity Immune System Diseases

Age range

19 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.

Treatment and study plan

Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)

Drug

Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)

Drug

Primary outcomes

Bioequivalence based on AUC and Cmax

Time frame: 19 days

Sponsors and collaborators

Lead sponsor

Sandoz

Industry

Registry information

Official study title

Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

Important dates

Study start: 1989
Primary completion: 1990
Study completion: 1990
First posted: Jun 4, 2009
Registry last updated: Mar 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed